TY - JOUR
T1 - Identification of tumor suppressor candidate genes by physical and sequence mapping of the TSLC1 region of human chromosome 11q23
AU - Pletcher, Mathew T.
AU - Nobukuni, Takahiro
AU - Fukuhara, Hiroshi
AU - Kuramochi, Masami
AU - Maruyama, Tomoko
AU - Sekiya, Takao
AU - Sussan, Tom
AU - Isomura, Minoru
AU - Murakami, Yoshinori
AU - Reeves, Roger H.
N1 - Funding Information:
We thank Dr Yusuke Nakamura for valuable discussion and assistance with BAC sequencing. This work was supported in part by R01 HD24605 (R.H.R.), by a Grant-in Aid for the Second Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare, Japan (Y.M.), by a Grant-in-Aid for Special Projects for Cancer Research from the Ministry of Education, Science, Sports and Culture of Japan (Y.M.), and by a Grant from the Promotion of Fundamental Studies in Health Sciences of the Organization for Pharmaceutical Safety and Research (OPSR) of Japan (Y.M.). T.N., H.F. and M.K. are recipients of Research Resident Fellowships from the Foundation for Promotion of Cancer Research of Japan.
PY - 2001/8/8
Y1 - 2001/8/8
N2 - Loss of heterozygosity for a locus on human chromosome 11q22-23 is observed at high frequency in non-small cell lung carcinoma (NSCLC). Introduction of a 1.1 Mb fragmented yeast artificial chromosome (YAC) mapping to this region completely suppresses the tumorigenic properties of a human NSCLC cell line, A549. Smaller fragmented YACs give partial but not complete suppression. To further localize the gene(s) responsible for this partial suppression, a bacterial artificial chromosome (BAC) and P1-based artificial chromosome (PAC) contig was constructed, completely spanning the candidate region. End sequence generated in the construction of the BAC/PAC contig identified a previously unmapped EST and served to order genomic sequence contigs from the publicly available Celera Genomics (CG) and Human Genome Project (HGP) efforts. Comparison showed that CG provided larger contigs, while HGP provided more coverage. Neither CG nor HGP provided complete sequence coverage, alone or in combination. The sequence was used to map 110 ESTs and to predict new genes, including two GenScan gene predictions that overlapped ESTs and were shown to be differentially expressed in tumorigenic and suppressed A549 cell lines.
AB - Loss of heterozygosity for a locus on human chromosome 11q22-23 is observed at high frequency in non-small cell lung carcinoma (NSCLC). Introduction of a 1.1 Mb fragmented yeast artificial chromosome (YAC) mapping to this region completely suppresses the tumorigenic properties of a human NSCLC cell line, A549. Smaller fragmented YACs give partial but not complete suppression. To further localize the gene(s) responsible for this partial suppression, a bacterial artificial chromosome (BAC) and P1-based artificial chromosome (PAC) contig was constructed, completely spanning the candidate region. End sequence generated in the construction of the BAC/PAC contig identified a previously unmapped EST and served to order genomic sequence contigs from the publicly available Celera Genomics (CG) and Human Genome Project (HGP) efforts. Comparison showed that CG provided larger contigs, while HGP provided more coverage. Neither CG nor HGP provided complete sequence coverage, alone or in combination. The sequence was used to map 110 ESTs and to predict new genes, including two GenScan gene predictions that overlapped ESTs and were shown to be differentially expressed in tumorigenic and suppressed A549 cell lines.
KW - 11q23.3
KW - Genomic sequence analysis
KW - Non-small cell lung cancer
KW - P1-based artificial chromosome/bacterial artificial chromosome contig
KW - Tumor suppressor gene
UR - http://www.scopus.com/inward/record.url?scp=0035827919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035827919&partnerID=8YFLogxK
U2 - 10.1016/S0378-1119(01)00592-3
DO - 10.1016/S0378-1119(01)00592-3
M3 - Article
C2 - 11595164
AN - SCOPUS:0035827919
SN - 0378-1119
VL - 273
SP - 181
EP - 189
JO - Gene
JF - Gene
IS - 2
ER -